MK-1484

Merck Sharp & Dohme LLC · Phase 1 active Biologic

At a glance

Generic name	MK-1484
Also known as	SP'482
Sponsor	Merck Sharp & Dohme LLC
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001) (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MK-1484 CI brief — competitive landscape report
MK-1484 updates RSS · CI watch RSS
Merck Sharp & Dohme LLC portfolio CI